170 related articles for article (PubMed ID: 11494447)
21. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
[TBL] [Abstract][Full Text] [Related]
23. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
[TBL] [Abstract][Full Text] [Related]
25. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.
el-Far M; Fouda M; Yahya R; el-Baz H
J Physiol Biochem; 2004 Dec; 60(4):253-8. PubMed ID: 15957243
[TBL] [Abstract][Full Text] [Related]
26. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.
Monsalve-De Castillo F; Romero TA; Estévez J; Costa LL; Atencio R; Porto L; Callejas D
Clin Diagn Lab Immunol; 2002 Nov; 9(6):1372-5. PubMed ID: 12414777
[TBL] [Abstract][Full Text] [Related]
27. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Ozdemir F; Aydin F; Yilmaz M; Kavgaci H; Bektas O; Yavuz MN; Yavuz AA
J Exp Clin Cancer Res; 2004 Sep; 23(3):485-8. PubMed ID: 15595640
[TBL] [Abstract][Full Text] [Related]
28. Soluble interleukin-2 receptor levels in patients with non-Hodgkin's lymphoma or with acute leukemia.
Chang CS; Lin SF; Liu HW
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1988 May; 21(2):79-84. PubMed ID: 3264231
[TBL] [Abstract][Full Text] [Related]
29. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
Marri PR; Hodge LS; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Cerhan JR; Novak AJ; Ansell SM
Clin Cancer Res; 2013 Dec; 19(24):6812-9. PubMed ID: 24141626
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
32. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
Fujimura K; Ebinuma H; Fukamachi I; Ohwada C; Kawaguchi T; Shimizu N; Takeuchi M; Sakaida E; Jiang M; Nakaseko C; Bujo H
Clin Chim Acta; 2014 Mar; 430():48-54. PubMed ID: 24394293
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
[TBL] [Abstract][Full Text] [Related]
34. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
35. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
36. Soluble molecules as biological markers in Hodgkin's disease.
Nadali G; Vinante F; Chilosi M; Pizzolo G
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():99-105. PubMed ID: 9570686
[TBL] [Abstract][Full Text] [Related]
37. Age-dependent changes of serum soluble CD30 concentration in children.
Chrul S; Polakowska E
Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
[TBL] [Abstract][Full Text] [Related]
38. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
[TBL] [Abstract][Full Text] [Related]
39. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
40. [Usefulness of selected serum cytokines for monitoring compliance with a gluten-free diet in celiac patients].
Müller L; Szaflarska-Popławska A
Med Wieku Rozwoj; 2004; 8(1):43-51. PubMed ID: 15557696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]